A prospective, randomised, controlled, parallel arm, open phase IIa study on the efficacy and safety of the GnRH analogue triptorelin for HIV-1 reservoir reduction in HIV-1 infected male adult patients on suppressive ART

Trial Profile

A prospective, randomised, controlled, parallel arm, open phase IIa study on the efficacy and safety of the GnRH analogue triptorelin for HIV-1 reservoir reduction in HIV-1 infected male adult patients on suppressive ART

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Triptorelin (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Immune System Regulation
  • Most Recent Events

    • 27 Mar 2018 New trial record
    • 15 Mar 2018 Status changed from planning to recruiting.
    • 15 Mar 2018 According to an Immune System Regulation media release, the study comprises 26 + 26 patients from the Huddinge and Sodersjukhuset infection clinics in Stockholm.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top